AHA Scientific Sessions 2026 Abstract · Nov 2, 2026

Advanced Lipoprotein Characterization of Occult Atherogenic Risk in Tangier Disease: A Two-Patient Case Series

By Levy LC, Steuerwald M, Roth M et al.

Introduction: Tangier disease, caused by biallelic ABCA1 loss-of-function, is a rare cause of marked HDL deficiency with a prevalence of 1 in 640,000. Whether Tangier disease increases ASCVD risk remains controversial. Here we describe two genetically confirmed cases of Tangier Disease with ASCVD and demonstrate how advanced lipoprotein testing may provide insight into lipid-related risk for ASCVD. Patient Cases: Patient 1 is a 55-year-old White woman with a history of premature CAD requiring PCI in the setting of exertional angina at age 52 yrs (Table). She was active with a normal BMI, and had no history of diabetes, hypertension, smoking, or family history of premature CAD. A routine lipid profile was notable for very low HDL-C, minimally elevated LDL-C, and moderate triglyceride elevation. Advanced lipid testing demonstrated significantly elevated apoB, LDL-P, and sdLDL-C, discordant with her LDL-C value. HDL particle analysis revealed very low levels of apoA-I, HDL-P, and all HDL particle subtypes. Patient 2 is a 56-year-old Ashkenazi Jewish woman with a history of hypertension and prior smoking. Routine lipid panel revealed very low HDL-C with elevated LDL-C, elevated non-HDL-C, and normal triglycerides. LDL-P and apoB were also noted to be discordantly elevated in comparison to her LDL-C. ApoA-I and HDL-P were very low. She reported no prior cardiovascular events but was found to have a CAC score of 93 (94 th percentile for age/gender). Genetic testing was performed in both cases. In patient 1, genetic testing revealed biallelic ABCA1 mutations. In Patient 2, genetic testing was also notable for biallelic ABCA1 mutations as well as a heterozygous VUS in LDLR. Both patients were started on lipid lowering therapy including statins and ezetimibe with the goal of lowering LDL-C, non-HDL-C, and apoB. Four years after initial presentation, patient 2 had a repeat calcium score CT which demonstrated an increased CAC score of 219 (95 th percentile) for which daily low-dose aspirin was added. Discussion: The patients in both cases demonstrate discordant elevation of apoB and LDL-P relative to LDL-C, though the precise mechanism in each case is likely distinct. Patient 1 exhibits the classic Tangier pattern of triglyceride-enriched sdLDL predominance. Patient 2’s more significant LDL-C elevation and relatively larger LDL particle size is likely the result of her co-occurring LDLR VUS. In both cases, LDL-C alone may underrepresent atherogenic risk. The recent AHA/ACC Multisociety Dyslipidemia Management Guideline emphasizes the role of non-HDL-C and apoB to refine risk assessments and treatment targets which is directly applicable to the characterization of the residual risk seen in Tangier disease. In Tangier disease, for ASCVD risk reduction it is important to lower atherogenic lipoprotein levels which can be achieved with standard lipid-lowering therapies.

doi.org/10.1161/circ.154.suppl_1.9214Biomarkers

AgingResearch.News